Methodology
FISH
Test Description
Probes: FGFR2 (10q26.13)
Disease(s): Cholangiocarcinoma (bile duct cancer) and various solid tumors
Clinical Significance
FGFR2 fusions are under active clinical study in a range of solid tumors, with targeted therapy already available to certain cholangiocarcinoma patients. FGFR2 fusions occur at highest frequency in intrahepatic cholangiocarcinoma (iCCA), observed in 10-16% of patients. This lab-developed test uses a break-apart FISH probe to detect the presence of FGFR2 fusions (translocations). Fusion partners of FGFR2 are not specifically identified.
Specimen Requirements
- Bone marrow aspirate: N/A
- Peripheral blood: N/A
- Fresh, unfixed tissue: N/A.
- Fluids: N/A
- Paraffin block: Send paraffin block. Also send circled H&E slide for tech-only (required).
- Cut slides: H&E slide (required) plus 4 unstained slides cut at 4-5 microns. Circle H&E slide for tech-only.
Storage & Transportation
Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.
CPT Code(s)*
88374x1 automated or 88377x1 manual
Turnaround Time
3-5 days
Level of Service
Technical
Global
New York Approved
Yes
References
- Newsroom page, published April 20, 2020. Am J Managed Care website. https://www.ajmc.com/newsroom/-fda-approves-orphan-drug-pemigatinib-for-rare-bile-duct-cancer-cholangiocarcinoma. Accessed June 20, 2020